Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease

Investigative Radiology

Volumn 46, Issue 2, 2011, Pages 141-145

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Sano, Katsuhiro ^a   Sou, Hironobu ^a   Onohara, Kojiro ^a   Muhi, Ali ^a   Kitamura, Takatoshi ^a   Amemiya, Fumitake ^a   Enomoto, Nobuyuki ^a   Matsuda, Masanori ^a   Asakawa, Masami ^a   Fujii, Hideki ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

chronic liver disease; gadoxetic acid (gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid or gadoxetic acid); hepatocellular carcinoma; liver; MR imaging

Indexed keywords

CREATININE; GADOXETIC ACID;

AGED; ARTICLE; ARTIFACT; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMAGE QUALITY; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; LIVER CELL; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT;

EID: 78751620186     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181f9c487     Document Type: Article

References (22)

1. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase iii, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
2. Tanimoto A, Lee JM, Murakami T, et al. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009;19(suppl 5):S975-S989.
3. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol. 2008;18:457-467.
4. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging Invest Radiol 2010, 45, 96-103.
5. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology. 2010;256:151-158.
6. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
7. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199:177-183.
8. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
9. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.
10. Svensson J, Petersson JS, Stahlberg F, et al. Image artifacts due to a time-varying contrast medium concentration in 3D contrast-enhanced MRA. J Magn Reson Imaging. 1999;10:919-928.
11. Lufkin RB, Pusey E, Stark DD, et al. Boundary artifact due to truncation errors in MR imaging. Am J Roentgenol. 1986;147:1283-1287.
12. Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxy-benzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging. 2009;30:849-854.
13. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79:373-374.
14. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005;234:460-467.
15. Monzawa S, Ichikawa T, Nakajima H, et al. Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. Am J Roentgenol. 2007;188:147-153.
16. Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology. 2005; 42:14-16.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
18. Stern W, Schick F, Kopp AF, et al. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol. 2000;41:255-262.
19. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci. 1999;44:1330-1337.
20. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619-2621.
21. Heverhagen JT, Wright CL, Schmalbrock P, et al. Dose comparison of single versus double dose in contrast-enhanced magnetic resonance angiography of the renal arteries: intra-individual cross-over blinded trial using Gd-DTPA. Eur Radiol. 2009;19:67-72.
22. Zech CJ, Grazioli L, Jonas E, et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol. 2009;19(suppl 3):S753-S763.